Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation

Josep María Ribera, Olga García, Pau Montesinos, Salut Brunet, Eugenia Abella, Manuel Barrios, José González-Campos, Pilar Bravo, Maria Luz Amigo, Jesús María Hernández-Rivas

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)

Abstract

The main outcomes of the Programa Español para Tratamiento de Hemopatías (PETHEMA)-acute lymphoblastic leukaemia (ALL)-Ph-08 trial were described and compared with those of the historical PETHEMA-CSTIBES02 trial. The trials differed in imatinib dose (600 vs. 400 mg/d) and amount of chemotherapy (one vs. two consolidation cycles) before stem cell transplantation (SCT). All patients (n = 29) enrolled in the ALL-Ph-08 trial achieved complete remission (CR) (vs. 90% in CSTIBES02), and SCT was performed in CR in 90% (vs. 78%). The reduction in early death, relapse before SCT and transplant-related mortality observed in the ALL-Ph-08 trial resulted in an improved 2-year event-free survival (63% vs. 37%, P = 0·009). © 2012 Blackwell Publishing Ltd.
Original languageEnglish
Pages (from-to)78-81
JournalBritish Journal of Haematology
Volume159
Issue number1
DOIs
Publication statusPublished - 1 Oct 2012

Keywords

  • Acute lymphoblastic leukaemia
  • Imatinib
  • Philadelphia chromosome

Fingerprint Dive into the research topics of 'Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this